Establishing Site-Specific Solutions for Optimal Treatment Selection and Sequencing of Therapies in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Establishing Site-Specific Solutions for Optimal Treatment Selection and Sequencing of Therapies in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Interactive Practice Guide
Although many patients with chronic lymphocytic leukemia (CLL) respond to initial therapy and the 5-year survival rate has improved, disease progression occurs. However, there is a lack of consensus on optimal treatment sequencing in CLL leading to uncertainty regarding the long-term effects of sequencing decisions on progression-free survival, overall survival, and the durability of responses in various patient subsets. Selecting the most appropriate therapy for relapsed/refractory (R/R) CLL in an individualized manner requires careful consideration of first-line therapy, disease characteristics, patient comorbidities, adverse event profiles, and goals of therapy.
Moreover, navigating the evolving R/R CLL therapeutic landscape requires a multidisciplinary team to engage and educate patients and effectively monitor and manage treatment-related adverse events (TRAEs) to improve treatment adherence.
To help clinicians mitigate barriers to adopting guideline-concordant use of novel therapies and formulate individualized, long-term treatment plans for patients with R/R CLL, this interactive practice guide interweaves education and practical guidance for easy integration of the latest evidence within daily clinical processes and workflows.
Faculty: Nitin Jain, MD, Sameer A. Parikh, MBBS
Release Date:
Expiration Date: November 14, 2026
